Vanda Pharmaceuticals Inc. cash flow to debt ratio of -867.07% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Vanda Pharmaceuticals Inc.'s free cash flow has decreased 579.76% from $-16.25M last year to $-110.44M, signaling decreasing performance

Vanda Pharmaceuticals Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Vanda Pharmaceuticals Inc.'s debt has decreased relative to shareholder equity from 0.02 last year to 0.00 today, signaling strengthened financials

Vanda Pharmaceuticals Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in Vanda Pharmaceuticals Inc.'s latest filing, so interest coverage cannot be calculated.

Vanda Pharmaceuticals Inc.'s profit margin has decreased (1.24K%) in the last year from -9.51% to -127.41%, signaling decreasing performance

Vanda Pharmaceuticals Inc.'s short-term assets of $347.26M exceed its short-term liabilities of $145.16M

Vanda Pharmaceuticals Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Vanda Pharmaceuticals Inc.'s return on equity of -84.95%, is lower than 15.00%, indicating bad performance

Vanda Pharmaceuticals Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Vanda Pharmaceuticals Inc. had positive net income in 3 out of 5 years, indicating stable and consistent earnings

Vanda Pharmaceuticals Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Vanda Pharmaceuticals Inc. has negative free cash flow, indicating cash burn

Vanda Pharmaceuticals Inc.'s yearly earnings has decreased 1.07K% since last year from $-18.90M to $-220.47M, signaling decreasing performance

Vanda Pharmaceuticals Inc.'s yearly revenue has increased 8.72% since last year from $198.77M to $216.10M, signaling increasing performance

ROIC -74.73% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Vanda Pharmaceuticals Inc.'s 3-year revenue CAGR of -5.29% is negative, indicating declining revenue over the past 3 years

Vanda Pharmaceuticals Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Vanda Pharmaceuticals Inc. had positive ROE in 3 out of 5 years, indicating consistent and reliable returns on equity

Vanda Pharmaceuticals Inc. has insufficient data to evaluate this check.

Vanda Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Vanda Pharmaceuticals Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Vanda Pharmaceuticals Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Vanda Pharmaceuticals Inc. is overvalued relative to its fair value price of -1.78 based on Earnings Fair Value model

Vanda Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Vanda Pharmaceuticals Inc. has a price-to-book ratio of 1.37x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Vanda Pharmaceuticals Inc. has a price-to-sales ratio of 1.40x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue